NEXICLON

Serial Number 88672961
Registration 6890002
700

Registration Progress

Application Filed
Oct 29, 2019
Under Examination
May 5, 2020
Approved for Publication
Mar 10, 2020
Published for Opposition
Mar 10, 2020
Registered
Nov 1, 2022

Trademark Image

NEXICLON

Basic Information

Serial Number
88672961
Registration Number
6890002
Filing Date
October 29, 2019
Registration Date
November 1, 2022
Published for Opposition
March 10, 2020
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Nov 1, 2022
Registration
Registered
Classes
005

Rights Holder

TRIS PHARMA, INC

03
Address
Attn: Jonathan Provoost
2031 US Highway 130
Monmouth Junction, NJ 08852

Ownership History

TRIS PHARMA, INC

Original Applicant
03
Monmouth Junction, NJ

TRIS PHARMA, INC

Owner at Publication
03
Monmouth Junction, NJ

TRIS PHARMA, INC

Original Registrant
03
Monmouth Junction, NJ

Legal Representation

Attorney
Cathy A. Kodroff

USPTO Deadlines

Next Deadline
1015 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20221101)
Due Date
November 01, 2028
Grace Period Ends
May 01, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

33 events
Date Code Type Description Documents
Nov 1, 2022 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Nov 1, 2022 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Sep 30, 2022 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Sep 29, 2022 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Sep 29, 2022 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Sep 15, 2022 IUAF S USE AMENDMENT FILED Loading...
Sep 29, 2022 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Sep 15, 2022 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Apr 29, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 27, 2022 EX4G S SOU EXTENSION 4 GRANTED Loading...
Apr 27, 2022 EXT4 S SOU EXTENSION 4 FILED Loading...
Apr 27, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jan 3, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 6, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 4, 2021 EX3G S SOU EXTENSION 3 GRANTED Loading...
Nov 4, 2021 EXT3 S SOU EXTENSION 3 FILED Loading...
Nov 4, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 4, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 2, 2021 EX2G S SOU EXTENSION 2 GRANTED Loading...
May 2, 2021 EXT2 S SOU EXTENSION 2 FILED Loading...
May 2, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 7, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 5, 2020 EX1G S SOU EXTENSION 1 GRANTED Loading...
Nov 5, 2020 EXT1 S SOU EXTENSION 1 FILED Loading...
Nov 5, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 5, 2020 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Mar 10, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Mar 10, 2020 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 19, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Feb 4, 2020 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 3, 2020 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 2, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Nov 1, 2019 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations, namely, pharmaceutical preparations containing the drug clonidine, intended for the treatment of various indications, including, hypertension, Tourette's Syndrome, Attention Deficient Hyperactivity Disorder and Autism
First Use Anywhere: 20210800
First Use in Commerce: 20210800

Classification

International Classes
005